tbuckley/cabot-search huggingface dataset:
Neurodevelopmental Outcomes in Children After the Fontan Operation
Authors: Joseph M. Forbess, Karen J. Visconti, David C. Bellinger, Richard A. Jonas
Journal: Circulation (2001)

Background Previous studies of patients after the Fontan operation have reported IQ scores lower than population norms. In the past decade, changes have occurred both in surgical methods used and in the patient population undergoing Fontan palliation. The present study examined the impact of these changes on neurodevelopmental outcomes after Fontan. Methods and Results Neuropsychological tests were administered to 27 five-year-old children after Fontan. Mean age at repair was 2 years 4 months. The present sample was compared with an earlier Fontan group (EFG) of 133 patients who underwent surgery in the 1970s and 1980s. Mean age at repair for the EFG was 7 years 3 months. Compared with EFG, the present study sample was younger at Fontan ( P =0.0001) and more likely to have undergone a Norwood procedure ( P =0.02), a pre-Fontan bidirectional cavopulmonary anastomosis ( P &lt;0.001), and Fontan fenestration ( P =0.001). Although mean full-scale, verbal, and performance IQ scores were within 1 SD (15 points) of the population mean of 100 (93±16, 95±15, and 91±17, respectively), mean full-scale and performance IQ scores were significantly lower than this population mean ( P =0.03 and P =0.01, respectively). Conclusions Compared with a historical cohort of Fontan patients from this institution, a staged approach to Fontan earlier in life is not detrimental to neurodevelopmental outcome. Neurodevelopmental outcomes in children after Fontan are in the normal range, but performance remains lower than the general population.
Immune Cell Functions in Industrial Workers after Exposure to 2,3,7,8-Tetrachlorodibenzo-p-dioxin: Dissociation of Antigen-Specific T-Cell Responses in Cultures of Diluted Whole Blood and of Isolated Peripheral Blood Mononuclear Cells
Authors: Martin Ernst, D. Flesch-Janys, I. Morgenstern, A. Manz
Journal: Environmental Health Perspectives (1998)

A comparative analysis was performed of the phenotype and function of peripheral blood leukocytes of two age-matched cohorts of industrial workers in chemical plants, one of which was exposed occupationally to high concentrations of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).Median actual TCDD burdens were 1 16 ng/kg and 4 ng/kg, respectively.The phenotype analysis of peripheral blood mononuclear cells (PBMC) revealed no significant differences in the proportions of CD3, CD4, or CD8+ T lymphocytes, of CD16+ natural killer cells, and of CD19+ B lymphocytes.However, in PBMC of the TCDD-exposed workers, the proportion of CD8+ memory T cells (CD45R0+) was significantly higher, and that of lymphocytes with naive phenotype (CD45RA+) was significantly lower than in PBMC of the control group.Polyclonal and antigen-specific T-cell activation was assessed in parallel in isolated PBMC as well as in diluted whole blood cultures.In both culture systems the polyclonally stimulated cytokine release did not differ significantly between the two cohorts; however, we found a significantly reduced interferon 'y release in diluted whole blood cultures but not in isolated PBMC cultures of the TCDD-exposed cohort when we performed an antigen-specific T-cell stimulation with tetanus-toxoid.Therefore, we propose that exposure of individuals to high doses of TCDD can partially impair in the "blood milieu" those T-cell/monocyte interactions that are essential for antigen-specific T-cell responses, whereas isolated PBMC of the same donors appear functionally less affected.
Venereal warts vs Bowen disease. A histologic and ultrastructural study of five cases
Authors: A. Lupulescu
Journal: JAMA (1977)

Verrucous growths of the genitalia in young patients are usually condylomata acuminata. In five cases this type of genital lesion, viewed by light microscopy, showed dysplastic cellular changes of Bowen disease, a diagnosis that was further confirmed by electron microscopy. Bowen disease should be included in the differential diagnosis of verrucous lesions of genitalia in young people and should be ruled out by histologic examination. (<i>JAMA</i>237:2520-2522, 1977)
A comparison of the WHO 2004 and 2010 classification systems in pancreatic neuroendocrine tumors (PNET).
Authors: Aakanksha Asija, Ashwin Reddy Sama, James Casey, Jocelyn Andrel Sendecki, Nancy Lewis, Harish Lavu, Jordan Michael Winter, Jonathan Robert Brody, Edith P. Mitchell, Charles Yeo, Anthony Prestipino, Madhavan V. Pillai
Journal: Journal of Clinical Oncology (2014)

e15170 Background: PNETs are rare tumors with multiple classification systems. We compared the WHO 2004 and 2010 classification systems in predicting mortality, metastasis and associations with mortality. Methods: Descriptive statistics were calculated for all patient characteristics for 50 patients. The relationship between the WHO 2004 and WHO 2010 grading was investigated using an exact Chi squared test. WHO grade categorization was next explored by vital status, by the exact method, in order to determine if there was a difference in survivorship and metastasis by grading system. Associations between death and categorical variables were tested using exact methods and between death and continuous variables by the Wilcoxon test. Survival was explored using Cox Proportional Hazards regression (COX). Results: 62% were female and the average age was 60 years. The WHO grades were significantly associated with one another (p <0.001). In Table 1, both grading systems were strongly associated with predicting mortality; all cases of mortality were in the higher grades. The 2010 grades do slightly better than 2004 grades in predicting metastasis as metastases occur only in high grades (G2 and G3). Comorbidities, margins and site were not significantly different by mortality; patients with lymphovascular or perineural invasion had significantly higher mortality. Mitotic Index was significantly different with a median of 0 in live patients versus 15 in deceased, p <0.001. This was similarly borne out in the survival analysis using COX, where for every one unit increase in Mitotic Index, there was about a one third increase in the hazard of death (p = 0.001). There was no significant difference in survival by tumor size, comorbidities, or margins. Conclusions: The WHO 2010 grading system is strongly associated with predicting mortality and performs better in predicting liver metastasis than the 2004 grading system. Vital Status and WHO grades (G). Vital status p-value Alive/ censored (n=43) Deceased (n=7) WHO 2004 <0.001 Poorly differentiated endocrine carcinoma 0 4 Well differentiated (WD) endocrine carcinoma 12 3 WD endocrine tumor with benign behavior 7 0 WDET with uncertain behavior 24 0 WHO 2010 <0.001 G 1 23 0 G 2 20 1 G 3 0 6
Open letter to the new CMO.
Journal: BMJ (1983)

As our new Chief Medical Officer at the Department of Health and Social Security, you will bring to the job the originality, zest, and humour that you have shown in your earlier career.But at the risk of boring you and adding to an already large pile of suggestions may I send you my own good wishes and thoughts for the New Year.I have put these under five headings without implying any priority among them, and anyway virtually all of them are interconnected. Hospital serviceThe decline of Britain's hospital service began when Barbara Castle was Secretary of State for Health.The enmity between the ancillary workers and the consultants was succeeded by the former obtaining unjustified power- breaking the camaraderie that had existed for decades, undermining the geographical whole time concept, and destroying morale among the hospital specialists, driving many of them to get their major satisfactions elsewhere, often in private practice.Rhetoric, some might say, and certainly failure of manage- ment nerve is not universal-but where it has occurred (as at many of our teaching hospitals) the evidence is clear: the offhand, unkempt porter at the gate, the grubby corridors, the stained and torn upholstery, the unswept car parks, the
JAMES SYME (1799-1870)—RUBBERCHEMIST AND GENERAL SURGEON
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.
Authors: Anthony B. El-Khoueiry, Ignacio Melero, Todd S. Crocenzi, Theodore Hobart Welling, Thomas Cheung Yau, Winnie Yeo, Akhil Chopra, Joseph Grosso, Lixin Lang, Jeffrey Anderson, Christine Marie Dela Cruz, Bruno Sangro
Journal: Journal of Clinical Oncology (2015)

LBA101 The full, final text of this abstract will be available at abstracts.asco.org at 2:00 PM (EDT) on Friday, May 29, 2015, and in the Annual Meeting Proceedings online supplement to the June 20, 2015, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.
OC-093 The Effects of Faecal Microbiota Transplantation on the Innate Immune System and Epithelial Tight Junction Expression in Chronic Refractory Pouchitis
Authors: J Landy, H O Al-Hassi, E R Mann, S T Peake, S D McLaughlin, Z L Perry-Woodford, P J Ciclitira, J Nicholls, S K Clark, S C Knight, A L Hart
Journal: Gut (2013)

<h3>Introduction</h3> Faecal microbiota transplantation (FMT) may be beneficial in IBD. A durable change in recipients' microbiota following FMT has been demonstrated. No previous study has assessed the immunological effects of FMT. We aimed to assess the immunological effects of FMT in patients with chronic refractory pouchitis. <h3>Methods</h3> FMT was performed via nasogastric tube. Mucosal biopsies samples were collected at pouchoscopy from eight patients with chronic refractory pouchitis before and four weeks after FMT. The epithelium was identified following incubation with EDTA and lamina propria dendritic cells (DCs) were identified following collagenase digestion. Epithelial cells were identified as pancytokeritin positive cells and expression of ZO-1, claudin 1 and claudin 2 were measured by multicolour flow cytometry. DC were identified as an HLA DR+, lineage- (CD3-,CD14-,CD16-,CD19-,CD34-) population. Expression of TLR 2, 4 and 5, β7 and CCR 9, and CD40 were measured by multicolour flow cytometry. Cytokines were assessed by multiplex ELISA of biopsy supernatants. The t-test was used in statistical analysis. <h3>Results</h3> There was a tendency for increased expression of claudin 2 (18.6% +- 11.4% v 39.6% +-13.4%, p = 0.3). Lower levels in lamina propria DC expression of TLR4(45.8% +- 6.5% v 33.6% +- 6.9%) and TLR 5(35.5% +-12.2% v 23.3% +-11.5%) as well as β7 expression (39.9% +-7.6% v 31.9% +-4.5%) were not statistically significant. There were no changes in the levels of IL2, 4, 6, 10, TNF, IFN or IL17 in the supernatant of mucosal biopsies before or 4 weeks after FMT. However, a rise in IL10 (9.1pg/ml +-1.2 v 12.5pg/ml +-2.9, p = 0.2) was noted following FMT. <h3>Conclusion</h3> There were no significant alterations in epithelial tight junction expression or immunological factors studied following FMT. In chronic refractory pouchitis, faecal transplantation may not be effective in altering the aberrant immunological response. <h3>Disclosure of Interest</h3> None Declared
Bronchial Reactivity in Asthmatic Children at High and Low Altitude: Effect of Budesonide
Authors: A. L. Boner, A. Comis, M. Schiassi, P. Venge, G. L. Piacentini
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

Inhaled steroids may control bronchial inflammation in asthmatics exposed to allergens. In this study we evaluated whether prophylactic budesonide would prevent relapse of asthma in children re-exposed to offending allergens at sea level, after a period of antigen avoidance at high altitude. Thirty children received either budesonide (200 µg b.i.d.) or placebo (double-blind). Following a 4-wk baseline period and 2 wk of treatment at high altitude, children were treated for 3 mo at sea level. Methacholine challenge and pulmonary function studies were performed before and after baseline period, after the 2 wk of treatment in the mountain environment, and at the end of treatment. ECP serum levels were evaluated after the baseline period and at the end of treatment. PEFR and symptoms were recorded in a diary card during the study. The increase in methacholine provocative dosage was greater, although not significant (p = 0.096), in the budesonide than in the placebo group after the treatment at high altitude and remained higher at the end of the treatment (p = 0.04). ECP levels increased in both the groups with no significant difference. Our results confirm that budesonide, in addition to its efficacy in treating pre-existent airway inflammation, is effective in preventing the increase of reactivity in asthmatic children re-exposed to allergens.
JEALOUSY AS A DISEASE.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Access to Care
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Light on leukaemia?
Journal: BMJ (1970)

Shiraki contrasts the disseminated necrosis of the newborn with the centrilobular congestion and destruction of the liver in congestive heart failure, and concludes that the effect of hypoplasia of the left heart and coarctation of the aorta cannot be adequately explained by venous back-pressure.He suggests that the basic cause of the liver damage is a decreased total hepatic blood flow as well as a lowered blood pressure in the portal vein and hepatic artery.In fact, this is the cause of much of the parenchymatous degeneration in the nutmeg liver of heart failure.Perhaps death supervenes too rapidly in these infants for the complete picture to develop.The incidence of localized necrosis in association with defects in the abdominal wall is probably explained by circulatory insufficiency of that part of the liver contained in the defect.This work should stimulate further research into the effect of ischaemia on the liver cells of the newborn infant.Light on Leukaemia?Discovery of a qualitative difference between leukaemia and normal cells may herald a dramatic change of approach in chemotherapy.Such differences have been sought for years, and there have been many claims.More recently antigenic
The Essentials of Otology.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE COUNCIL ON PHARMACY AND CHEMISTRY.
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CREOSOTE NOT A SPECIFIC.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract C74: Temozolomide-perillyl alcohol conjugate is cytotoxic for glioma cancer stem cells
Authors: Niyati Jhaveri, Fabienne Agasse, Florence M. Hofman, Thomas C. Chen
Journal: Cancer Research (2013)

Abstract Glioblastoma multiforme (GBM), the most malignant glioma, is a highly invasive tumor which is usually fatal within 2 years. The chemotherapeutic agent of choice is temozolomide (TMZ); however glioma patients inevitably become resistant to TMZ and tumors recur. Tumor recurrence has been associated with highly invasive, chemoresistant cancer stem cells (CSC) which is resistant to TMZ. We have constructed a new chemical entity by conjugating TMZ to perillyl alcohol (POH) via a carbamate bond. This compound, TMZ-POH, contains POH, a naturally occurring monoterpene that reduces tumor cell migration and has anti-tumor properties against gliomas as well as other cancers. In the studies presented here we demonstrate that TMZ-POH is cytotoxic to CSCs without affecting normal stem cells. The mechanism of TMZ-POH induced cytotoxicity is mediated in part through the DNA damage response pathway and apoptosis. Furthermore, the TMZ-POH conjugate is 5 to 10 fold more effective in inducing cell death compared to TMZ, POH or the mixture of these agents. Our data show that TMZ-POH is a promising novel compound directed against cancer stem cells and therefore important for the treatment of drug resistant, recurrent gliomas. Citation Format: Niyati Jhaveri, Fabienne Agasse, Florence M. Hofman, Thomas C. Chen. Temozolomide-perillyl alcohol conjugate is cytotoxic for glioma cancer stem cells. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Invasion and Metastasis; Jan 20-23, 2013; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2013;73(3 Suppl):Abstract nr C74.
“2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung.” Brian L. Graham, Vito Brusasco, Felip Burgos, Brendan G. Cooper, Robert Jensen, Adrian Kendrick, Neil R. MacIntyre, Bruce R. Thompson and Jack Wanger. Eur Respir J 2017; 49: 1600016.
Authors: Brian Graham, Vito Brusasco, Felip Burgos, Brendan Cooper, Robert Jensen, Adrian Kendrick, Neil Macintyre, Bruce Thompson
Journal: European Respiratory Journal (2018)